The A.P.P.A.® PROJECT: formulation, stability and quality study of a pediatric galenic preparation for the treatment of sickle cell disease at Saint Damien Hospital in Haiti.

Francesca Baratta; Irene Depellegrini; Maria Beatrice Iozzino; Romel Cajuste; Pierre Saint Jean; Emanuela Ambreck; J. Kempf; Paola Brusa

doi:10.13135/2531-8772/3670

The A.P.P.A.® PROJECT: formulation, stability and quality study of a pediatric galenic preparation for the treatment of sickle cell disease at Saint Damien Hospital in Haiti.

Auteurs

Francesca Baratta
Irene Depellegrini
Maria Beatrice Iozzino
Romel Cajuste
Pierre Saint Jean
Emanuela Ambreck
J. Kempf
Paola Brusa

DOI :

https://doi.org/10.13135/2531-8772/3670

Résumé

In Haiti sickle cell disease is a widespread disorder and it is associated with a high mortality. Because of this, in 2016, N.P.H. St Damien Hospital in Port-au-Prince required a medicine based on hydroxyurea to treat pediatric patients. Since there is no specific formulation on the market, in the context of the A.P.P.A.^® Project at the University of Turin, a galenic formulation was studied along with a method to assess its quality and its stability over time. The medicine was introduced on site following the training of local staff and it is now dispensed to nearly 50 patients.